1Adreasen NC,Black DW.Introductory Textbook of Psychiatry[M].3rd.American Psychiatric Publishing,Inc.2001:713,719.
2Wang PS,Shneeweiss S,Aom J,et al.Risk of death in elderly users of conventional vs atypical antipsychitics medications[J].N Engl J Med,2005,353(22):2 335.
3Kane JM,Marder SR.Comprehansive Textbook of Psychiatry[M].8th ed.Philadelphia:Lippincott Williams Wilkins,2005:1 469.
4Davus JM,Chen N,Click ID.A mental-analysis of the efficacy of second generation antipsychotics[J].Arch Gen Psychiatry,2003,160(6):553.
5Geddes J,Freemantle N,Harrison P,et al.Atypical antipsychotics in the treatment of schizophrenia:systematic overview and meta-regression analysis[J].BMJ,2000,321(7273):1 371.
6Lieberman JA,Stroup TS,McEvov JP,et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia[J].N Engl J Med,2005,353(12):1 209.
1Indication and Usage. GEOI)ON (pfizer) (ziprasidone HCI).GEODON for Injection (ziprasidone mesylate)[ EB/OL ].http://www. FDA. gov,2000 - 07 - 19.
2Important prescribing information for addiction treatment specialists[EB/OL]. http://www. FDA. gov, 2001 - 04 - 11.
3Draft Consensus Guideline. Safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals [ EB/OL ].http://www. FDA. gov,2002 02 - 07.
4Drug-induced QT interval prolongation and torsades de pointes[EB/OL]. http ://www. FDA. gov, 2003 05 - 20.
5FDA disclaimer : novartis pharmaceuticals corporation, important drug warning [EB/OL]. http ://www. FDA. gov, 2000 - 07 -07.
619ougla.s C, Throckmorton MD. Cardiovascular drugs that prolong the QT interval[EB/OL]. http ://www. F'DA. gov, 2003 05-20.
7Jansen Pharmaceutica Research Foundation. Important safety and efficacy information [EB/OL]. http://www. FDA. gov,1998 06-26.
8FDA approve arsenic trioxide for leukenia treatment in record time for a cancer drug development program[EB/OL]. http://www. FI)A. gov,2000 - 07 - 19.
